The incredible pace of innovation in new drugs and technologies, coupled with regulation and ethics, makes special demands on the industry. Pharma continues to try and fill its pipeline, while biotech and medical technologies make heavy demands on private equity and licensee partners to fund the discovery and development process.

It’s crucial to use a legal adviser with real experience of the sector and in-depth understanding of both scientific and business issues. Members of our team have advanced scientific qualifications and industry experience. We have clients in the pharma, biotech and medtech sectors, as well as those who support these sectors with services and technology.

We have an integrated European team providing co-ordinated advice to our many international clients in the sector. We have a track record of helping clients achieve domestic and cross-border mergers and acquisitions, and advising on equity and debt fundraisings. We help our clients to monetise their assets through creative partnering with early-stage entrepreneurial and established companies, and by providing intellectual property and tax advice. Our patent litigation team advises clients on validity and infringement issues across Europe. We also have an established and specialist international arbitration practice, with experience in many jurisdictions.

Experience


Univercells

Advised on a series A investment in Belgian biotech company Univercells.

First Water

Advised the shareholders of First Water on its acquisition by Scapa Group for consideration of up to £15.3m payable depending on performance in 2016, 2017 and 2018.

Intrapharm Laboratories Ltd

Advised Intrapharm Laboratories Ltd management team and all of its shareholders on the disposal of the company to German pharmaceutical company RIEMSER Pharma GmbH.

Imperial Innovations Group plc

Advised Imperial Innovations Group plc and SV Life Sciences on a £19 million series A investment in Kesios Therapeutics.

Drug discovery company

Advised the shareholders of a privately held drug discovery company on its acquisition by C4X Discovery Holdings plc in exchange for shares in C4X.

LDC

Advised long-standing client LDC together with the management team on the sale of Penn Pharma in a transaction worth £127m.

Institutional investors

Advised the syndicate of institutional investors, which included Imperial Innovations and Invesco Perpetual, on the £581m flotation of Circassia on the London Main Market.  

2